Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4\~6 weeks after drug administration.
The purpose of this study is 1. to determine whether genomic effects on antidepressant response differed by class of drug, 2. whether genomic differences between drug responders and nonresponders predict the response of antidepressant and 3. to construct the prediction model for antidepressant treatment in order to aid to select the their genetically matching drugs.
Age
19 - 89 years
Sex
ALL
Healthy Volunteers
Yes
Samsung Medical Center
Kangnam, Seoul, South Korea
Start Date
February 1, 2003
Primary Completion Date
December 1, 2018
Completion Date
December 1, 2018
Last Updated
December 31, 2015
1,000
ESTIMATED participants
SSRI treated group
DRUG
non-SSRI treated group
DRUG
Lead Sponsor
Samsung Medical Center
NCT07360600
NCT06793397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions